No Priors: Artificial Intelligence | Technology | Startups How AI can make drug discovery fail less, with Daphne Koller from Insitro
Mar 2, 2023
Daphne Koller, CEO of Insitro and a former Stanford professor, discusses the transformative role of AI in drug discovery. She shares her journey from tech to biotech, emphasizing the potential of induced pluripotent stem cells. Koller dives into how machine learning can tackle significant challenges in drug development, including the complexities of diseases like schizophrenia. She also highlights the importance of creating a collaborative culture that bridges biology and computer science for meaningful innovation.
AI Snips
Chapters
Transcript
Episode notes
Machine Learning's Broad Impact
- Machine learning's transformative potential is vast and impactful across various fields.
- Its effectiveness depends on strategic application, not as a universal solution.
AI's Pendulum Swing
- Deep learning's raw processing power initially overshadowed interpretable AI.
- Now, a synthesis of both approaches, combining deep learning with causal reasoning and interpretability, is emerging.
Leaving Stanford for Coursera
- Daphne Koller left Stanford for Coursera, intending a two-year leave, but the impact and timing felt too crucial to leave.
- Stanford's strict policy led to her resigning an endowed chair, a decision her mother questioned.